Compare Organon & Co. Common Stock (OGN) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Invesco S&P 500 High Div Low Volatility ETF trades at $49.88 (market cap $3.20B). The key difference: Organon & Co. Common Stock and Invesco S&P 500 High Div Low Volatility ETF are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Invesco S&P 500 High Div Low Volatility ETF for 126 Days on average.
| OGN | SPHD | |
|---|---|---|
Market Cap | $3.62B | $3.20B |
Volume | 2,892,999 | 1,075,230 |
Sector | Health | — |
52-Week High | $13.81 | $53.55 |
52-Week Low | $5.70 | $46.96 |
Typical Hold Time | 0 Days | 126 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SPHD, the Invesco S&P 500 High Dividend Low Volatility ETF, trades at $49.29, up 0.1% on the day. Technical indicators show a mixed picture with a bullish overall signal but bearish moving averages, while the RSI suggests mild overbought conditions. The ETF focuses on high dividend yields and low volatility, attracting income-focused investors, though recent news highlights performance comparisons with peers like SCHD.
The outlook for SPHD hinges on its dividend strategy amid market volatility. Opportunities include steady income for retirees, but risks involve underperformance versus growth-focused ETFs and sensitivity to interest rate changes. Investors should weigh the trade-off between yield and total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
